-
Agios to Decide on Mitapivat as Possible Sickle Cell Therapy by Mid-year
With enrollment in a proof-of-concept clinical trial on hold due to COVID-19, Agios says it will decide on next steps for mitapivat in SCD around June. Click here to find out more.
Do you think it is realistic for this clinical trial to resume this summer?
Sorry, there were no replies found.
Log in to reply.